Open access
Aug 2026
Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption
RAS, a frequently mutated cancer-driver gene, has been the focus of intensive research, with numerous inhibitors developed to target RAS and its signalling molecules. With the advent of approved subtype-specific RAS inhibitors targeting KRASG12C mutation, the development of RAS inhibitors that are effective regardless...
Y. Yoshikawa, Hirokazu Kubota, S. Matsumoto et al.
· Nature Communications · 0 citations